Background. Intracranial hemorrhage after liver transplantation is an infrequently reported complication but one which can have devastating consequences. Methods. We performed a retrospective cross-sectional analysis of all liver transplants performed between January 2010 and June 2015 at a single high-volume institution using a prospectively maintained electronic database and query of the electronic medical record. Cases of intracranial hemorrhage were adjudicated as either spontaneous intraparenchymal hemorrhage(IPH) or extra-axial hemorrhage (EAH). Patients with confirmed intracranial hemorrhage were compared with all other liver transplant recipients. Risk factors were identified by univariate analysis and logistic regression models for IPH and EAH. Results. Thirty-one (5.2%) of 595 liver transplant recipients developed an intracranial hemorrhage within 12 months of transplantation, 15 IPH and 16 EAH. The majority of intracranial hemorrhages were diagnosed within 1 month of transplantation. Eight (26%) intracranial hemorrhage patients died during hospitalization. Fourteen (45%) intracranial hemorrhage patients died within 1 year of transplantation and 1-year mortality was greater than in patients without intracranial hemorrhage (11.2%, P < 0.01). Female sex (adjusted odds ratio [OR], 3.291; 95% confidence interval [CI], 1.092-9.924; P = 0.034), higher pretransplant bilirubin (adjusted OR, 1.037; 95% CI, 1.006-1.070; P = 0.020), and greater increase in pretransplant to posttransplant systolic blood pressure (adjusted OR, 1.029; 95% CI, 1.006-1.052; P = 0.012) were associated with posttransplant IPH. Lower pretransplant serum fibrinogen level (adjusted OR, 0.988; 95% CI, 0.979-0.998; P = 0.017) was associated with posttransplant EAH. Conclusions. Postoperative blood pressure control and pretransplant fibrinogen levels may be modifiable risk factors for preventing posttransplant intracranial hemorrhage.
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(Transplantation 2018;102: 448-453) I ntracranial hemorrhage after liver transplant is a potentially devastating complication. The overall incidence is ill defined, and there are limited reports in the literature concerning etiology and risk factors. 1, 2 In the general population, intracranial hemorrhage may occur in association with coagulopathy, acute hypertension, or chronic hypertension. [3] [4] [5] [6] In particular, control of systolic hypertension has been central in efforts to reduce the incidence of intraparenchymal hemorrhage (IPH) and manage IPH when it occurs. 7, 8 Based on these observations, we hypothesized that similar risk factors may be associated with posttransplant intracranial hemorrhage and represent potentially modifiable targets for clinical intervention.
In this study, we sought to define the overall incidence of intracranial hemorrhage within 12 months after transplant among all patients undergoing liver transplantation during a 66-month period at a high-volume center. We sought to identify demographic and clinical variables associated with 2 classes of posttransplant intracranial hemorrhage, spontaneous IPH and extra-axial hemorrhage (EAH), which includes both subdural hemorrhage and subarachnoid hemorrhage.
MATERIALS AND METHODS
Data were extracted on all patients who underwent liver transplantation from January 1, 2010, through June 30, 2015. Transplantation data, including clinical events after transplant, were prospectively recorded in an electronic database. The occurrence of any form of intracranial hemorrhage was a clinical event specifically recorded in this database. Query of the database was used to identify those patients diagnosed with an intracranial hemorrhage within a 12-month period after liver transplant. Laboratory, medication administration, and blood pressure data were extracted from the electronic medical record by the Northwestern Medicine Enterprise Data Warehouse analytics team. Neuroimaging studies from each identified case of intracranial hemorrhage were reviewed by board certified radiologists and a board-certified attending neurologist with expertise in neurologic critical care and intracranial hemorrhage. Hemorrhages were adjudicated to either of 2 categories based on the anatomical origin of the hemorrhage: intraparenchymal or extra-axial. IPH originates within the substance of the brain, whereas EAH originates intracranially but outside of the brain tissue itself. EAHs included subdural and subarachnoid hemorrhages; no epidural hemorrhages were identified in this cohort. We categorized intracranial hemorrhages into IPH and EAH and analyzed them separately because they likely have different causative mechanisms and, in the general population, have unique risk factors. 6, 9 Hemorrhage characteristics on initial diagnostic neuroimaging studies were recorded and included location, IPH volume, EAH thickness (thin vs thick [≥10 mm greatest thickness]), and the occurrence of radiographic brain herniation (uncal, central, tonsillar, or subfalcine herniation) or severe brain compression (brain tissue distortion requiring emergent surgical or medical intervention). The presenting neurologic symptoms, indications for neuroimaging, and patient outcomes at hospital discharge were extracted by chart review. Intracranial hemorrhages determined to be chronic at the time of transplantation (eg, chronic subdural hemorrhages) or lesions not representing primary hemorrhages (eg, intracranial cavernous malformations, acute ischemic strokes with hemorrhagic transformation, intracranial device related hemorrhages) were excluded from analysis. We also excluded patients undergoing repeat liver transplantation.
Data on intraoperative blood product transfusion and thromboelastography were not electronically recorded before 2012 and, therefore, were not available for analysis in this study. Our intraoperative approach to transfusion involves administering packed red blood cells to maintain a hemoglobin goal level of 10 g/dL. Transfusion of platelets and plasma-derived products is avoided before graft arterial reperfusion to minimize the risk of hepatic artery thrombosis. Thromboelastography is used to guide intraoperative management of clotting and fibrinolysis status and aminocaproic acid is used to treat elevated fibrinolytic activity. Heparin infusion may be used when a relative hypercoagulable state is suspected; our protocol provides a recommended heparin dose guided by international normalized ratio (INR) (200 units/hour for INR < 1.5 and 100 units/hour for INR 1.6-1.7). Of note, because of depressed production of antithrombin, Protein C, and Protein S during cirrhosis, the INR may be more reflective of the degree of liver disease than bleeding tendency in cirrhosis and it is even possible for cirrhotic patients with elevated INR to be hypercoagulable by thromboelastography. 10 For each patient, we identified whether heparin infusion or aminocaproic acid was used during transplantation.
Patients with confirmed intracranial hemorrhage were compared with all other liver transplant recipients (controls). Baseline patient characteristics and demographic data including pretransplant Model for End-Stage Liver Disease (MELD) score, living versus deceased donor status, and intraoperative data were extracted from the transplant database. Pretransplant and posttransplant laboratory variables and systolic blood pressure values were extracted from the hospital electronic medical record by computerized query. The most deranged laboratory values according to clinical significance (for example, the lowest platelet and fibrinogen level, the highest International Normalized Ratio) and highest systolic blood pressure (SBP) in the 24-hour period before transplant were selected to represent the pretransplant period. The most deranged laboratory values and highest SBP in the 96-hour period after transplant were selected to represent the posttransplant period. The 96-hour period was selected for analysis because this represented the duration after transplant in which each patient who ultimately had an intracranial hemorrhage was still hospitalized and receiving regular blood pressure monitoring and laboratory studies. Using blood pressure values from the pretransplant and posttransplant periods, we calculated the change in SBP between the periods.
Continuous variables are reported as mean (standard deviation) or median (interquartile range). Categorical variables are reported as proportions. Comparisons of continuous variables between groups (controls, IPH, and EAH) were made using 1-way analysis of variance test for normally distributed variables and Kruskal-Wallis test for nonnormally distributed variables. Groups were compared pairwise using either one-way analysis of variance or Kruskal-Wallis post hoc tests adjusted for multiple comparisons. Post hoc Tukey honest significant difference tests were used for normally distributed variables and post hoc Bonferroni adjusted multiple comparison tests were used for nonnormally distributed variables. Categorical variables were compared between each group of intracranial hemorrhage and controls by Fisher exact test. Separate logistic regression models for IPH and EAH were built to identify variables independently associated with each type of hemorrhage. Variables with univariate P values less than 0.15 between cases and controls were assessed for model inclusion. In the case of the MELD score, we assessed the individual component variables for model inclusion. The final parsimoniously adjusted models were created using the backward stepwise approach with a removal criterion of probability of F-to-remove ≥0.1. This approach ensured an adequate number of events per variable to meet published recommendations for robust logistic models. 11 We considered P less than 0.05 to be significant.
Statistical analysis was performed using SPSS v.23 (IBM, Armonk, NY). The Northwestern University Institutional Review Board approved this study.
RESULTS
The study cohort included 595 liver transplant recipients (378 male, 56.5 (11.0) years, 24 acute liver failure, MELD at the time of transplant 24 ). Within 1 year of liver transplant, 31 (5.2%) patients developed an intracranial hemorrhage, 15 IPH and 16 EAH. Two cases of chronic subdural hematoma, 1 case of acute ischemic stroke with hemorrhagic transformation, and 1 case of chronic cavernous malformation were excluded from analysis. Invasive intracranial pressure monitors were used in 2 patients before liver transplantation; intracranial hemorrhage was not observed on neuroimaging in these patients. Diagnosis of IPH occurred a median of 16 (5-33) days posttransplant, and diagnosis of EAH occurred a median of 9 4-16 days posttransplant. In 14 IPH and 13 EAH cases, either acute onset of neurologic symptoms or previous neuroimaging confirmed that hemorrhage onset occurred posttransplantation. In the remaining 4 cases (1 IPH and 3 EAH), neuroimaging was performed because of prolonged depressed mental status after transplantation, and the possibility of intraoperative hemorrhage onset could not be excluded. Table 1 summarizes the indications for neuroimaging and the initial neurologic symptoms of the intracranial hemorrhage patients. Table 2 summarizes the radiographic hemorrhage characteristics. Neuroimaging within 1 year of transplantation was acquired in 124 (22%) control patients at a median of 8 (3-36) days. Among controls, the most frequent indications for neuroimaging were fall, headache, and altered mental status.
Neurosurgical and neurocritical care consultations were obtained in each hemorrhage case. Repeat neuroimaging to evaluate hemorrhage evolution was obtained in 30 patients. One patient died of brain herniation before repeat neuroimaging. Three EAH and 4 IPH patients had cerebrovascular imaging. Brain magnetic resonance imaging was obtained in 11 EAH and 8 IPH patients. An underlying structural lesion as the cause of hemorrhage was not identified in any case. No patient with intracranial hemorrhage had bacteremia or fungemia before or at the time of hemorrhage diagnosis. Platelet infusion was given in 3 EAH and 3 IPH cases in response to platelet count below 100 thousand/μL. Coagulation factors were given in 5 EAH and 1 IPH case in response to INR greater than 1.7. Craniectomy with hematoma evacuation was performed in 2 EAH patients. One IPH patient had a decompressive hemicraniectomy, and 1 IPH patient had a decompressive hemicraniectomy with hematoma evacuation.
Eight (26%) of patients who developed intracranial hemorrhage died during hospitalization. Intracranial hemorrhage that progressed to brain herniation contributed to death in 6 (19%) of these patients. Fourteen (45%) of patients who developed intracranial hemorrhage were discharged to home or acute rehabilitation; of these, 4 had disabling hemiparesis or aphasia at discharge and 10 had minimal residual symptoms attributable to the hemorrhage. Among the nine (29%) patients discharged to a skilled nursing or long-term acute care facility, 2 were bed-bound and 3 were not independently mobile due to neurologic injury. Among those who had neurosurgical intervention, 1 patient was discharged to acute rehabilitation with hemiparesis and moderate aphasia, 1 patient was discharged to a long-term acute care hospital in persistent coma, and 2 patients died in hospital with palliative care after several weeks of persistent coma. At 1 year thousand/μL, P = 0.079) was the only posttransplant laboratory measure that suggested a difference between groups (P < 0.15). There was a trend toward more frequent aminocaproic acid use during transplantation in EAH patients than in controls (13% vs 3.4%, P = 0.11). However, there was no difference in pretransplant fibrinogen level between those who received aminocaproic acid and those who did not (P = 0.65).
IPH was associated with female sex (adjusted odds ratio [OR], 3.291; 95% confidence interval [CI], 1.092-9.924; P = 0.034), higher pretransplant serum total bilirubin level (adjusted OR, 1.037; 95% CI, 1.006-1.070; P = 0.020), and greater increase in pretransplant to posttransplant SBP (adjusted OR, 1.029; 95% CI, 1.006-1.052; P = 0.012). Pretransplant INR and pretransplant systolic blood pressure did not meet criteria for inclusion in the final IPH model. An increase in pretransplant to posttransplant SBP of 28 or more mm Hg was 80% sensitive and 53% specific for IPH. EAH was associated with lower pretransplant serum fibrinogen level (adjusted OR, 0.988; 95% CI, 0.979-0.998; P = 0.017). Intraoperative aminocaproic acid, pretransplant and posttransplant platelet count did not meet criteria to remain in the final model. Pretransplant serum fibrinogen level lower than 148 mg/dL was 81% sensitive and 53% specific for EAH.
DISCUSSION
The overall incidence of intracranial hemorrhage within 12 months of liver transplant in this cohort was 5.2%. This incidence is similar to that reported by Wang et al ( a Post hoc Tukey honest significant difference tests were used for normally distributed variables and post hoc Bonferroni adjusted multiple comparison tests were used for non-normally distributed variables. Categorical variables were compared between each group of intracranial hemorrhage and controls by Fisher exact test. b Polycystic liver/kidney disease patients have an increased risk of intracranial aneurysms. Diagnostic evaluation for polycystic liver/kidney disease in this patient was performed 6 years before transplantation at another institution. Records from the pretransplantation evaluation state no intracranial aneurysm was discovered during the patient's diagnostic evaluation for polycystic liver/kidney disease.
Female sex, higher pretransplant serum bilirubin level, and greater increase in SBP between pretransplant to posttransplant levels were associated with IPH. Lower pretransplant serum fibrinogen level was associated with EAH. Although our study was not designed to elucidate the physiologic mechanisms leading to intracranial hemorrhage after liver transplantation, we identified mechanistically plausible associations. IPH associated with cerebral hyperperfusion and acute systemic hypertension has been described in the posterior reversible encephalopathy syndrome, eclampsia, and after carotid stenting and carotid endarterectomy. 5, 12 In these conditions, the magnitude of acute change in blood pressure and the extent to which cerebral blood flow regulation (cerebral autoregulation) is impaired seems to correlate to symptoms better than absolute blood pressure. 5 In our cohort, the average SBP increased from normotension pretransplant to stage 1 hypertension posttransplant 7 whereas those who had IPH experienced a significantly greater increase in SBP. Others have also reported an increase in blood pressure within 24 hours of liver transplantation. Liver transplantation eventually results in correction of portal hypertension and reversal of the pathophysiological mechanisms that lead to hyperdynamic circulation in cirrhotics. 13 However, this process may take up to 12 months to achieve. [14] [15] [16] Cerebral autoregulation impairments that have been described in association with cirrhosis may further complement our findings. Studies have suggested that impaired cerebral autoregulation is associated with lower blood pressure and more severe Child-Pugh scores in patients with cirrhosis. 17, 18 These observations raise the possibility that the IPH patients in our cohort, who had significantly lower pretransplant blood pressures and higher serum bilirubin, may also have had more impaired cerebral autoregulation. The combination of chronically impaired cerebral autoregulation and increased cerebral blood flow after transplantation could place patients with large increases in blood pressure at risk for cerebral hyperperfusion and IPH. Alternatively, cirrhosis may have masked some patients' comorbid predisposition to hypertension, which subsequently manifested after transplantation and contributed to the risk of future IPH. The observed association between systolic blood pressure changes and IPH in our study could also merely represent an epiphenomenon rather than a causal mechanism.
In our patients with EAH, the association with low pretransplant fibrinogen is mechanistically plausible as it may have contributed to inadequate clot formation in the immediate posttransplant period. In this setting, subdural or subarachnoid hemorrhages may have resulted from even innocuous trauma. Once formed, these hemorrhages are prone to expansion and potential symptomatic presentation. 9 Mitigating the intracranial hemorrhage risk factors identified in this study might seem intuitive but caution is warranted. For example, EAH may be difficult to predict because these lesions are highly related to trauma. Keeping fibrinogen levels artificially elevated in all patients before liver transplantation might inappropriately expose patients to the risks and complications of treatment to avoid the uncommon EAH. In fact, some have advocated that providing treatments merely to correct abnormal coagulation studies should be avoided because it exposes patients to risks including acute lung injury, infection and thrombosis. 19, 20 In terms of increased blood pressure and risk of posttransplant IPH, it may be more reasonable for the clinician to recognize and address relative posttransplant hypertension on an individual patient basis than enforce a standard blood pressure range for all patients. Our data suggest that it may be reasonable for the clinician to evaluate the risks and benefits of instituting blood pressure interventions when the increase in pretransplantation to posttransplantation SBP exceeds 28 mm Hg.
There are a number of limitations to our study. This study represents a single center experience and it is unclear if it can be generalized to other transplant centers. Furthermore, the incidence of intracranial hemorrhage was rather low and therefore the number of cases relatively modest. However, our series represents more cases of IPH (15) than the combined number of cases (13) from the 2 previously published series on the topic. 1, 2 We also describe EAH in the posttransplant population, which to our knowledge has not previously been studied. Although intracranial hemorrhage is a potentially devastating complication of liver transplantation, the infrequent occurrence represents a challenge to studying this disease. Future research into the mechanisms of and interventions for posttransplantation intracranial hemorrhage might benefit from the collection of mechanistically plausible variables in a national database.
Like the series by Wang et al and Wijdicks et al, we found univariate data to suggest a relationship between intracranial hemorrhage, thrombocytopenia, and coagulation measures. However, these variables did not remain significant in regression models. Unfortunately, intraoperative transfusion and thromboelastography data were not available for analysis in the entire cohort since these data were only consistently recorded after January 2012. We were unable to confirm the association between intraoperative transfusion requirements and risk of intracranial hemorrhage suggested by Wang et al. We also found no data to support an association between posttransplant intracranial hemorrhage and bacteremia as suggested by Wijdicks et al. It should also be noted that not every patient in our cohort had neurologic imaging after liver transplantation. Therefore, it is possible that some patients in the control group had asymptomatic intracranial hemorrhages.
CONCLUSIONS
The overall incidence of postoperative intracranial hemorrhage within 12 months of liver transplantation in this cohort was 5.2% and was associated with worse 1-year posttransplant mortality. Regardless of whether intracranial hemorrhage occurred, systolic hypertension shortly after liver transplantation appeared to be common. Female sex, higher pretransplant total serum bilirubin level, and greater change in SBP from baseline after transplant were associated with IPH. Lower pretransplant fibrinogen level was associated with EAH. While these associations may inform the clinician regarding a potentially disastrous complication, an individualized approach with specific attention to the potential adverse effects of intervention is warranted.
